Tumor induced osteomalacia - A long way toward correct diagnosis and management.
Fibroblast growth factor -23
Hypophosphatemia
Phosphaturic mesenchymal tumor
Spinal involvement
Tumor induced osteomalacia
Journal
Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
02
01
2022
revised:
28
02
2022
accepted:
05
03
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Tumor-induced osteomalacia (TIO) is an uncommon type of osteomalacia associated with phosphaturic mesenchymal tumors (PMTs). Due to nonspecific symptoms, the diagnosis and appropriate management of the disease is often delayed for many years. Involvement of spine with TIO associated tumors is exceedingly rare. We present a 53-year-old woman with a 10-year history of bone pain, muscle weakness and multiple bone fractures that markedly impaired her quality of life. Biochemical evaluation revealed hypophosphatemia due to renal phosphate wasting and elevated plasma fibroblast growth factor 23 (FGF-23) concentration indicating PMT. It was found using
Identifiants
pubmed: 35281212
doi: 10.1016/j.bonr.2022.101180
pii: S2352-1872(22)00015-8
pmc: PMC8914328
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101180Informations de copyright
© 2022 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that the case report description was realized in the absence of any commercial or financial relationship that could represent a potential conflict of interest.
Références
Calcif Tissue Int. 2021 Jan;108(1):128-142
pubmed: 32504138
Sci Rep. 2021 Jan 19;11(1):1819
pubmed: 33469091
Osteoporos Int. 2020 Jul;31(7):1383-1387
pubmed: 32185436
Calcif Tissue Int. 2021 Aug;109(2):147-156
pubmed: 33818653
Nat Rev Dis Primers. 2017 Jul 13;3:17044
pubmed: 28703220
Bone Rep. 2017 Sep 20;7:90-97
pubmed: 29021995
J Clin Neurosci. 2019 May;63:234-239
pubmed: 30660478
Osteoporos Int. 2017 Jul;28(7):2187-2193
pubmed: 28341900
Clin Imaging. 2019 Jul - Aug;56:114-123
pubmed: 31029010
J Mol Endocrinol. 2021 Feb;66(2):R57-R65
pubmed: 33295878
Clin Nucl Med. 2015 Aug;40(8):642-6
pubmed: 26053726
J Bone Miner Res. 2002 Jun;17(6):1102-10
pubmed: 12054166
BJR Case Rep. 2016 Nov 02;2(4):20150497
pubmed: 30460030
Endocr J. 2015;62(9):811-6
pubmed: 26135520
J Bone Miner Res. 2021 Apr;36(4):627-635
pubmed: 33338281
Endocr J. 2017 Jul 28;64(7):675-683
pubmed: 28450684
J Clin Neurosci. 2013 Aug;20(8):1057-61
pubmed: 23618679
Radiol Med. 2021 Dec;126(12):1609-1618
pubmed: 34453276
Bone. 2021 Nov;152:116064
pubmed: 34147708
Pediatr Endocrinol Rev. 2019 Sep;17(1):17-34
pubmed: 31599133
Radiol Case Rep. 2021 Feb 17;16(4):989-993
pubmed: 33664928
Endocr Connect. 2019 Mar;8(3):266-276
pubmed: 30726771
J Bone Miner Res. 2012 Sep;27(9):1967-75
pubmed: 22532501
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619895162
pubmed: 31850815